South Africa and the United States will try out a new HIV vaccine to help prevent the spread of the virus. They have started to sign up people to join the testing of this medicine in a controlled experiment.
The National Institutes of Health (NIH), a research organization in the United States, has found that.
The VIR-1388 vaccine helps the body’s T-cells, which are a part of the immune system. T-cells patrol and check other cells for issues.
The vaccine is designed to teach the immune system to make special cells called T-cells. These T-cells can identify HIV and tell the immune system to fight back and stop the virus from causing long-lasting infection.
The vaccine testing is financially supported by the NIH, the Bill and Melinda Gates Foundation, and the US company Vir Biotechnology.
The research will include 95 people who do not have HIV. They will be chosen from four places in South Africa and six places in the US.
The first findings from the vaccine study will be shared in late 2024. However, a few people will stay in the study for an additional three years.
In 2020, the NIH stopped testing a different HIV vaccine in South Africa because a review showed that it didn’t work to stop HIV from spreading.
Date:
South Africa to begin testing an HIV vaccine
